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The strategy put forward in the Calman–Hine report ‘A policy
framework for commissioning cancer services’ (Department of
Health, 1994) proposes that patients with cancer should be treated
only in hospitals with enough staff, resources and collective
expertise for optimum treatment of the specific cancer. The report
relied, in part, on evidence that the best care for cancer patients
depended on having a team of specialists and a minimum work-
load for each specialist that ensured that they maintained and
developed their expertise. In general terms this meant that the
expected pattern of development of cancer services would result in
cancer units, mainly in district general hospitals, which would
have sufficient workload to maintain expertise in treating
commoner cancers, and cancer centres which, while performing
the functions of a unit, would treat the less common cancers, and
would also act as a source of specialization not usually found in a
district general hospital.
Implementation of this policy means that health authorities have
to alter the present pattern of services, which means they need to
know which hospitals would benefit from more investment and
development, and which should have services restricted or altered
by pooling their resources with other hospitals.
In the Anglia and Oxford region this process started by estab-
lishing the current workload of hospitals, and at the same time a
series of meetings were held involving clinical staff with the aim
of deciding what kinds of services should be provided for which
cancers. The Anglia and Oxford NHS Executive initially have
considered lung, gastrointestinal, breast, skin, urological cancers,
gynaecological cancers, brain and central nervous system, haema-
tological cancer, children’s cancers and head and neck cancers.
The health authorities had expressed a particular interest in the
performance of individual hospitals.
While there are many aspects of hospital performance, the East
Anglian Cancer Registry is able to provide information on patient
survival by individual hospital as they collect information on
tumour stage at diagnosis and perform active follow-up of
patients, thus ensuring accurate survival information with the
added ability to adjust for case mix differences. This allows
uniform analyses over different cancer sites to be performed, so
that groups of patients for whom implementation of the
Calman–Hine report will be the most effective (or not effective)
can be identified.
MATERIALS AND METHODS
All invasive cancers for the sites fitting our inclusion criteria
described below, diagnosed between 1989 and 1993 (to allow
survival analyses to be performed for patients followed up until
the end of 1998) and registered by the East Anglian Cancer
Registry were identified. The inclusion criterion was defined as all
cancer sites being considered by the Anglia and Oxford NHS
Executive for which the registry has an adequate (at least 70%)
proportion of cancers staged over the period. Thus we included
colon, rectal, breast, melanoma, bladder and ovarian cancers.
Active follow-up of patients is carried out by the Registry at
regular intervals (3 years after diagnosis, 5 years after diagnosis
and then every 5 years until death), so vital status 3 years after
diagnosis was known for almost all (98.7%) of the 16 367 patients
identified, and after 5 years for 80.4% of patients. Patients with
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fewer than 5 years of follow-up available, or those lost to follow-
up, were entered into the analysis as censored cases. All registra-
tions are reviewed and, where possible, staged by the medical
director (a clinical oncologist) of the registry, thus ensuring consis-
tency of staging in the population over the study period. Cases
were staged according to the TNM classification of malignant
tumours (Hermanek and Sobin, 1987) using all the staging infor-
mation available including clinical and pathological information.
Some patients, especially the elderly, did not have enough infor-
mation in the records for staging (see Table 2). These patients are
included in the analysis as ‘unstaged’.
For local purposes, the data were initially analysed by individual
hospital (results not presented here). The data were then grouped
so that hospitals with radiotherapy and oncology departments
(Addenbrooke’s in Cambridge, the Norfolk and Norwich Hospital,
and Ipswich Hospital) [group 1] (7000 patients) could be compared
with the six district general hospitals without radiotherapy and
oncology departments [group 2] (7527 patients). Hospitals that are
not district general hospitals are usually small and are mostly
community hospitals dealing with small numbers of patients. In East
Anglia there are five such hospitals, including one private hospital.
Patients attending these, along with other privately treated and extra
regionally treated patients, were excluded from the analysis because
the numbers were too small to form meaningful groups of their own.
In total they covered 11% (1840 patients) of the potential study popu-
lation. If a patient attended more than one hospital then they were
assigned to the hospital where the primary treatment was delivered.
Cox’s proportional hazards regression models (Cox, 1972) were
analysed to investigate survival differences for patients treated at
group 1 compared to group 2 hospitals adjusting for sex, age (in
10-year age bands) and tumour stage at diagnosis. As the group 1
hospitals were usually hospitals treating large numbers of patients
(high workload hospitals), the relative importance of specializa-
tion and hospital workload was also investigated using Cox’s
proportional hazards regression. Sub-analyses were performed to
compare the data both adjusted and unadjusted for tumour stage,
and in two age groups: under 75 and 75+ years, under the assump-
tion that aggressive curative treatment attempts would be more
likely in younger patients.
For the sub-groups where significant differences in hazard were
found, survival curves were produced using adjusted conditional
probabilities (Nieto and Coresh, 1996), with adjustment for the
covariates sex, age (in 10-year age bands) and tumour stage. These
adjusted conditional probabilities illustrate the survival we would
expect in the group 2 hospital patients if they had the same
covariate composition as the group 1 hospital patients.
Table 1 Patients diagnosed 1989–1993: number of cases and percentage
seen at group 1 hospitals by tumour type, hospital group and age stratum
Diagnosis Age Group 1 Group 2 Total
group (3 hospitals) (6 hospitals) cases
Breast <75 2093 (49%) 2220 4313
75+ 648 (51%) 615 1263
Total 2741 (49%) 2635 5576
Ovary <75 336 (47%) 383 719
75+ 139 (51%) 131 270
Total 475 (48%) 514 989
Colon <75 907 (46%) 1045 1952
75+ 750 (46%) 898 1648
Total 1657 (46%) 1943 3600
Rectal <75 553 (44%) 691 1244
75+ 353 (45%) 426 799
Total 906 (45%) 1117 2023
Bladder <75 401 (51%) 377 778
75+ 428 (58%) 307 735
Total 829 (55%) 684 1513
Melanoma <75 319 (49%) 377 656
75+ 73 (43%) 97 170
Total 392 (47%) 434 826
Table 2 Patients diagnosed 1989–1993: percentage of patients presenting at each TNM tumour stage (UICC classification) at diagnosis by tumour type and
age stratum. Hospital groups are shown separately: % in group 1 first and then % in group 2 in brackets.
Diagnosis Age % % % % % Not
group Stage 1 Stage 2 Stage 3 Stage 4 staged
Breast <75 43% (44%) 42% (39%) 7% (7%) 5% (6%) 4% (3%)
75+ 18% (21%) 37% (32%) 17% (15%) 9% (10%) 19% (22%)
Total 37% (39%) 41% (38%) 10% (9%) 6% (7%) 7% (7%)
Ovary <75 23% (28%) 14% (11%) 41% (36%) 11% (12%) 12% (13%)
75+ 12% (12%) 9% (10%) 36% (28%) 13% (12%) 30% (39%)
Total 20% (24%) 13% (11%) 39% (34%) 11% (12%) 17% (20%)
Colon <75 8% (7%) 37% (38%) 28% (30%) 18% (17%) 9% (8%)
75+ 7% (6%) 35% (36%) 22% (25%) 16% (13%) 20% (21%)
Total 8% (7%) 36% (37%) 25% (28%) 17% (15%) 14% (14%)
Rectal <75 20% (15%) 26% (32%) 28% (28%) 16% (12%) 11% (12%)
75+ 18% (15%) 27% (26%) 18% (19%) 12% (11%) 24% (30%)
Total 19% (15%) 26% (30%) 25% (25%) 14% (12%) 16% (19%)
Bladder <75 37% (44%) 23% (17%) 14% (18%) 6% (7%) 20% (13%)
75+ 35% (38%) 24% (15%) 15% (16%) 7% (8%) 19% (24%)
Total 36% (41%) 23% (16%) 15% (17%) 7% (7%) 20% (18%)
Melanoma <75 46% (49%) 23% (17%) 9% (11%) 5% (5%) 18% (18%)
75+ 21% (23%) 36% (20%) 25% (28%) 3% (5%) 16% (25%)
Total 41% (43%) 25% (18%) 12% (15%) 5% (5%) 17% (20%)RESULTS
A total of 14 527 patients were included in the final analysis. The
numbers of cancers by tumour type, age stratum and hospital
group are shown in Table 1. The group 1 hospitals treated between
45% (rectal) and 55% (bladder) of all cases and saw a similar
proportion of those aged under 75 years and those aged 75+ years.
Table 2 shows the percentage of cancers presenting in each tumour
stage within hospital group and age stratum. The stage distribution
for group 1 and group 2 hospitals was very similar.
Cox’s proportional hazards ratios comparing group 2 with group
1 hospitals with adjustment for age (in 10-year age bands) and sex
are shown in Table 3. Survival up to 5 years after diagnosis was
generally worse in group 2 hospitals and significantly so for rectal
tumours (model I). This difference was accentuated when an
adjustment for tumour stage was added to the model (model II)
indicating that survival within stage was worse in group 2 hospi-
tals, particularly for rectal and ovarian tumours.
Cox’s proportional hazards ratios comparing group 2 with group
1 hospitals calculated separately for each age group with adjust-
ment for age (within the age group), sex and tumour stage are
shown in Figure 1. For patients aged under 75 years, survival up to
5 years after diagnosis was worse in group 2 hospitals for the
tumour types and significantly so for breast, ovarian and rectal
tumours. For older patients, the trend of worse survival in group 2
hospitals was also evident except for breast cancer. The differ-
ences in older patients were not significant.
Figure 2A–C show plots of survival up to 5 years after diagnosis
in group 1 and 2 hospitals for breast, ovary and rectal tumours for
patients aged less than 75 years. The crude Kaplan–Meier survival
for group 1 and group 2 hospitals is plotted along with the adjusted
conditional probability of the survival we would expect in the
group 2 hospital patients if they had the same covariate composi-
tion as the group 1 hospital patients.
Hospital workload and hospital groups are not independent,
since the hospitals with radiotherapy and oncology departments
tend to have a larger workload. In order to distinguish the effects
of workload we analysed (the logarithm of) the individual hospital
workloads. Group 1 and group 2 hospitals were analysed sepa-
rately because the group 1 hospitals are almost always the
hospitals with the largest workload making a stratified analysis
meaningless. The hazard ratios shown in Table 4 suggest that
workload produces little significant effect independently from
hospital group, except for melanoma skin cancer at group 1 hospi-
tals where an inverse effect is seen.
DISCUSSION
For the patients included in this study, survival up to 5 years after
diagnosis was significantly worse for patients with ovarian, rectal
and breast tumours if they were aged under 75 years at diagnosis,
and had their main treatment in hospitals without radiotherapy and
oncology departments. These hazards have been adjusted for case
mix in terms of year of age, sex (where appropriate) and TNM
tumour stage at diagnosis. The differences in hazard can be seen
clearly in the survival graphs (see Figure 2).
Stage migration
The East Anglian Cancer Registry has very good information on
staging, and this has allowed us to use stage as a means of
adjusting for case mix. Nevertheless, staging is not complete, and
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Figure 1 Hazard ratios comparing survival up to 5 years after diagnosis in
group 2 relative to Group 1 hospitals by tumour and age group. Adjusted for
10-year age band, sex and stage at diagnosis
Table 3 Hazard ratios comparing survival up to 5 years after diagnosis in
Group 2 relative to Group 1 hospitals by tumour type
Diagnosis Model I Model II
Breast 1.03 (0.94–1.13) 1.04 (0.95–1.14)
Ovary 1.12 (0.97–1.30) 1.17 (1.01–1.35)a
Colon 0.98 (0.91–1.06) 1.04 (0.96–1.13)
Rectal 1.12 (1.01–1.25)a 1.19 (1.06–1.32)b
Bladder 1.09 (0.96–1.24) 1.09 (0.96–1.24)
Melanoma 1.13 (0.88–1.46) 1.17 (0.91–1.50)
aP ≤ 0.05, bP ≤ 0.01, cP ≤ 0.001. Adjusted for (I) 10-year age band and sex
and (II) 10-year age band, sex and TNM tumour stage (UICC classification)
at diagnosis.
Table 4 Hazard ratios comparing survival up to 5 years after diagnosis
using the logarithms of the individual hospital workloads, by tumour type and
hospital group
Hospital Diagnosis Hazard 95%
group ratio confidence
interval
Group 1 Breast 0.91 0.67–1.24
Ovary 1.48 0.79–2.74
Colon 1.20 0.78–1.85
Rectal 0.98 0.63–1.54
Bladder 0.81 0.57–1.16
Melanoma 1.80 1.06–3.06a
Group 2 Breast 1.07 0.93–1.23
Ovary 1.03 0.83–1.30
Colon 0.94 0.79–1.26
Rectal 0.97 0.80–1.19
Bladder 0.96 0.80–1.15
Melanoma 1.03 0.75–1.41
aP ≤ 0.05. Adjusted for 10-year age band, sex and TNM tumour stage (UICC
classification) at diagnosis.Five-year survival for cancer patients in East Anglia between 1989 and 1993 211
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Figure 2 Survival rates for patients < 75 years: (A) breast cancer, (B) ovarian cancer, (C) rectal cancer212 D Stockton and T Davies
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the accuracy of staging and completeness of staging could influ-
ence the results since misclassification results in stage migration.
For example, if staging of all tumours at a certain site in a hospital
is subject to bias and they are given an earlier stage classification
than they should have, then survival becomes apparently worse in
the earlier stage to which tumours are allocated, and in the more
advanced stage from which they have been withdrawn. Thus a
hospital with poorly reported histology or poor imaging is not only
likely to give patients inappropriate treatment but also bias its own
stage-adjusted results to make them look worse still. We found one
hospital where this appeared to have happened (in the reporting of
bladder cancers), but grouping of hospitals is likely to make this
effect small. The analysis in Table 3 indicates a survival advantage
for patients treated at group 1 hospitals even without an adjustment
for tumour stage, although it is not as marked as the stage-adjusted
analysis, which could indicate stage migration or within stage
survival variation.
Missing stage
Staging of cancers in East Anglia is supervised by the Medical
Director (a clinical oncologist) of the Registry and is thus likely to
be uniform, though still depending on adequate information.
Where this was not available, a tumour was classified as unstaged.
If a large number of tumours were unstaged (indicating complete
data unavailable), ‘unstaged’ would come to represent the average
tumour with a better survival than unstaged tumours where staging
was not possible because the patient was too ill. Hospitals where
this happened would thus have a contribution from an apparently
relatively good survival in unstaged patients and thus, in adjusting
for stage, their overall survival would improve because the
analysis treats ‘unstaged’ as quantitatively equivalent to true
stages. This was observed in one hospital where staging informa-
tion for 60% of one tumour was omitted by mistake with the
predicted effect. This was put right. The range of the proportion of
the remaining unstaged tumours is fairly small and, given the
pooling of hospital results, unlikely to affect estimates of mortality
hazard.
The reason for the survival advantage in specialist hospitals
being more evident in patients aged less than 75 years is not clear.
Survival as measured here takes into account age, sex and tumour
stage, but does not allow for differences in all cause mortality, i.e.
death from causes other than cancer will also have influence in the
survival figures. For elderly patients all cause mortality will
clearly be higher and it could be that this effect masks the differ-
ences seen between hospitals in the younger age groups. On the
other hand, it might be that the factors that are associated with
improved survival in younger patients are not applied to elderly
patients. A third possibility is that the smaller district general
hospitals are relatively better at treating elderly patients.
Another interpretation for the improved survival in specialist
hospitals in patients aged less than 75 years is that patients with a
better prognosis may be selectively referred to the group 1 hospi-
tals. This would leave an excess of poor prognosis and elderly
patients at the group 2 hospitals and thus make the survival appear
artificially worse. Conversely, the specialist hospitals may receive
advanced cases that require complicated treatment regimes making
survival appear worse. We have found no evidence that either of
these situations were systematically occurring (see Table 2), or if
they were, that they would be specific to patients diagnosed with
ovarian, breast or rectal cancer. Adjusting for age and stage at
diagnosis should also help eliminate any bias of this kind.
Selby et al (1996) recently published a review on papers looking
at outcome in terms of survival. From this review most of the
evidence suggests that there is usually some benefit from special-
ized cancer care and this would apply to treatment of tumours of
the breast, ovary, colon and rectum. However, it is inevitable that
evidence from many different studies is not consistent in defini-
tions of specialization and case mix, and that the information avail-
able on variables is likely to affect apparent outcome. The study
reported in this paper, using routinely collected cancer registration
data, has uniform definitions and it is clear which tumours are
more successfully treated in specialized hospitals, taking into
account stage as the indicator of case mix.
The initial purpose of the analysis was to assess the performance
of individual hospitals. There was wide variation that probably
reflected differences in case mix (not taken into account by stage),
random variation and the performance of one or two individuals.
However, when the results are pooled, these variations must lose
their impact; in particular, geographic confounders since the catch-
ment areas of the pooled hospitals overlap. The implication is that
there is a real difference, in this region and this period in the
performance of specialized and non-specialized hospitals for
certain tumours in patients aged under 75 years. This does not
simply appear to be due to bigger hospital workload for the tumour
site. For colon and rectal cancers there is evidence of more
chemotherapy being used for patients treated at the group 1 hospi-
tals over the study period which should be investigated further, but
the question of why these differences are seen cannot really be
answered with the routine data we have available.
The health authorities who have received this information are
naturally hesitant to take dramatic action based on this information
alone, but nevertheless it does lend more support to the view that
the strategy proposed in the Calman–Hine report is likely to be
beneficial.
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